KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Hold” from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been given a consensus recommendation of “Hold” by the nine research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $30.60.

A number of equities research analysts have weighed in on KALV shares. Needham & Company LLC downgraded KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Citizens Jmp downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Leerink Partners downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. HC Wainwright downgraded KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $37.00 to $27.00 in a report on Friday, May 1st. Finally, Stifel Nicolaus lifted their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th.

KalVista Pharmaceuticals Trading Down 0.1%

Shares of KALV opened at $26.79 on Thursday. KalVista Pharmaceuticals has a 12-month low of $9.83 and a 12-month high of $26.85. The company has a quick ratio of 5.10, a current ratio of 5.17 and a debt-to-equity ratio of 8.18. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12. The stock’s 50-day moving average price is $21.94 and its 200 day moving average price is $17.65.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $40.86 million during the quarter, compared to analysts’ expectations of $39.03 million. As a group, research analysts predict that KalVista Pharmaceuticals will post -0.96 earnings per share for the current year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,239 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total transaction of $59,960.42. Following the sale, the insider directly owned 150,260 shares of the company’s stock, valued at approximately $4,023,962.80. The trade was a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Benjamin L. Palleiko sold 10,926 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total value of $292,598.28. Following the sale, the chief executive officer directly owned 479,989 shares in the company, valued at $12,854,105.42. The trade was a 2.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 261,295 shares of company stock valued at $4,764,294 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth approximately $24,360,000. Emerald Advisers LLC boosted its holdings in shares of KalVista Pharmaceuticals by 30.2% in the 3rd quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after acquiring an additional 313,205 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth approximately $3,494,000. Blue Owl Capital Holdings LP acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth approximately $1,522,000. Finally, Emerald Mutual Fund Advisers Trust boosted its holdings in shares of KalVista Pharmaceuticals by 19.4% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 917,975 shares of the specialty pharmaceutical company’s stock worth $11,181,000 after acquiring an additional 149,003 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.